New England Biolabs Releases In Vitro Transcription Kit

New England Biolabs (NEB), Ipswich, Mass., has released an in vitro transcription kit for the generation of in vitro transcribed synthetic mRNA capped using the CleanCap Reagent AG from TriLink Biotechnologies, part of Maravai LifeSciences.

NEB’s portfolio of HiScribe in vitro transcription kits is designed to simplify workflows while producing high yields of RNA. The new HiScribe T7 mRNA Kit with CleanCap Reagent AG produces a high yield of mRNA with a Cap 1 structure in a single-step reaction for research and preclinical workflows. Messenger RNAs with Cap 1 structures are desirable for increased biological activity and reduced immunogenicity.

When manufacturing scales increase, NEB’s in vitro transcription kits, reagents, and enzymes can be obtained in large quantities, including GMP-grade* quality, allowing a seamless transition to large-scale therapeutic mRNA manufacturing, including vaccine production.

“Over the past year and a half, the use of synthetic mRNA vaccines has proven the effectiveness of mRNA as a therapeutic modality,” says Ted Davis, executive director of business and product development at NEB. “The new HiScribe T7 mRNA Kit with CleanCap Reagent AG combines NEB’s deep expertise in enzymology with TriLink’s novel CleanCap technology, enabling the acceleration of research and development by allowing scientists to easily generate high-quality mRNA and quickly screen many different molecules or designs.”

TriLink’s San Diego headquarters has grown to enable TriLink to meet the global demand for CleanCap reagent and supports several COVID-19 vaccine programs globally. TriLink also recently expanded manufacturing capabilities for nucleoside triphosphates, as well as for their contract development and manufacturing organization services, which now include plasmid DNA manufacturing for mRNA-based therapeutics and vaccine production.

“TriLink is proud to be included in the next generation of NEB in vitro transcription kits,” says Brian Neel, chief operating officer of TriLink Biotechnologies. “The inclusion of our CleanCap Reagent AG is a momentous step in the dissemination of CleanCap, making it even easier than before for scientists to generate superior performing mRNA, with a Cap 1 structure, in a single-pot reaction. The HiScribe platform is a perfect complement to CleanCap technology.”

For more information, visit New England Biolabs.

*“GMP-grade” is a branding term NEB uses to describe reagents manufactured at its Rowley, Mass., facility, where the company uses procedures and process controls to manufacture reagents under more rigorous conditions to achieve more stringent product specifications, and in compliance with ISO 9001 and ISO 13485 quality management system standards. NEB does not manufacture or sell products known as Active Pharmaceutical Ingredients (APIs), nor does it manufacture products in compliance with all the Current Good Manufacturing Practice regulations.

*“GMP-grade” is a branding term NEB uses to describe reagents manufactured at its Rowley, Mass., facility, where the company uses procedures and process controls to manufacture reagents under more rigorous conditions to achieve more stringent product specifications, and in compliance with ISO 9001 and ISO 13485 quality management system standards. NEB does not manufacture or sell products known as Active Pharmaceutical Ingredients (APIs), nor does it manufacture products in compliance with all the Current Good Manufacturing Practice regulations.